All In Biotech

Drug Trial Radar · NCT02710708

YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women

Last checked: Nov 19, 2026Latest source record: Jun 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,921

Actual

Start

May 27, 2016

Primary completion

Jul 3, 2018

Study completion Jul 3, 2018

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the safety profile of YAZ in Chinese women, including adverse drug reactions (ADRs). The secondary objectives are to investigate the rate of unintended pregnancies, the cycle control for subjects with and without preceding abortion, the bleeding pattern of subjects with and without preceding abortion (including the abortion-related bleeding pattern) and the efficacy in moderate acne vulgaris. Another objective is to investigate the effect on dysmenorrhea.

Conditions

  • Contraception

Interventions

  • EE20/DRSP (YAZ, BAY86-5300)Drug

    YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse drug reactions (ADRs)Time frame: 6 months

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Tianjin, China

  • Site not named

    Xiamen, Fujian, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Shenzhen, Guangdong, China

  • Site not named

    Liuzhou, Guangxi, China

  • Site not named

    Nanning, Guangxi, China

  • Site not named

    Shijiazhuang, Hebei, China

  • Site not named

    Changshacun, Henan, China

  • Site not named

    Wuhan, Hubei, China

  • Site not named

    Yueyang, Hunan, China

  • Site not named

    Changzhou, Jiangsu, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Wuxi, Jiangsu, China

  • Site not named

    Nanchang, Jiangxi, China

  • Site not named

    Xi'an, Shaanxi, China

  • Site not named

    Weifang, Shandong, China

  • Site not named

    Weifang, Shandong, China

  • Site not named

    Zibo, Shandong, China

  • Site not named

    Taiyuan, Shanxi, China

  • Site not named

    Chengdu, Sichuan, China

  • Site not named

    Ürümqi, Xinjiang, China

  • Site not named

    Kunming, Yunnan, China

  • Site not named

    Kunming, Yunnan, China

  • Site not named

    Hangzhou, Zhejiang, China

  • Site not named

    Hangzhou, Zhejiang, China

  • Site not named

    Hangzhou, Zhejiang, China

  • Site not named

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.